The secondary epidermal growth factor receptor (EGFR) T790M mutation is the most prominent mechanism that confers resistance to first-or second-generation EGFR tyrosine kinase inhibitors (TKIs) in lung cancer treatment. Although third-generation EGFR TKIs can suppress the kinase activity of T790M-positive EGFR, they still cannot eradicate EGFR-mutated cancer cells. We previously reported that a subpopulation of EGFR-mutant lung adenocarcinomas depends on enhanced autophagy, instead of EGFR, for survival, and in this study we explore another mechanism that contributes to TKI resistance. We demonstrate here that an EGFR-mutant lung adenocarcinoma cell line, H1975 (L858R+T790M), has a subset of cells that exhibits an epithelial-mesenchymal transition (EMT) phenotype and can thrive in the presence of third-generation EGFR TKIs. These cells depend on not only autophagy but also on the isomerase Pin1 for survival in vitro, unlike their parental cells. The Pin1 protein was expressed in an EGFR-mutant lung cancer tissue that has undergone partial EMT and acquired resistance to EGFR TKIs, but not its primary tumor. These findings suggest that inhibition of Pin1 activity can be a novel strategy in lung cancer treatment. Lung adenocarcinomas with an activating mutation in the epidermal growth factor receptor (EGFR) gene depend on EGFR signaling for survival and proliferation. Although most EGFR-mutant lung cancers initially respond to EGFR tyrosine kinase inhibitors (TKIs), such as gefitinib, erlotinib, or afatinib, disease progression almost inevitably develops, on average, 1 year after the initiation of TKI therapy. The most common mechanism of acquired resistance is the secondary EGFR T790M mutation, which is found in 50-60% of resistant tumors. 1 To overcome T790M-mediated resistance, third-generation EGFR TKIs, including CO-1686 (also known rociletinib) and AZD9291, have been developed. 2,3 These drugs have potent activity against both the common EGFR mutations (inframe deletions in exon 19 and the L858R mutation in exon 21) and the T790M mutation. Recent early-phase clinical trial data demonstrated a response rate of 60% in patients with T790M-positive tumors. 4,5 Although this response rate was much higher than that of patients with T790M-negative tumors (21-29%), acquired resistance to these agents has emerged even in T790M-positive tumors. 4, 5 We previously reported that two EGFR-mutated lung adenocarcinoma cell lines, HCC827 and HCC4006, have subpopulations of cells that display an epithelial-mesenchymal transition (EMT) phenotype and depend on enhanced autophagy, but not on EGFR activity, for survival. 6 We surmise that these EGFR-mutant cells devoid of EGFR dependency lie at the root of TKI resistance.
Lung adenocarcinomas with an activating mutation in the epidermal growth factor receptor (EGFR) gene depend on EGFR signaling for survival and proliferation. Although most EGFR-mutant lung cancers initially respond to EGFR tyrosine kinase inhibitors (TKIs), such as gefitinib, erlotinib, or afatinib, disease progression almost inevitably develops, on average, 1 year after the initiation of TKI therapy. The most common mechanism of acquired resistance is the secondary EGFR T790M mutation, which is found in 50-60% of resistant tumors. 1 To overcome T790M-mediated resistance, third-generation EGFR TKIs, including CO-1686 (also known rociletinib) and AZD9291, have been developed. 2, 3 These drugs have potent activity against both the common EGFR mutations (inframe deletions in exon 19 and the L858R mutation in exon 21) and the T790M mutation. Recent early-phase clinical trial data demonstrated a response rate of 60% in patients with T790M-positive tumors. 4, 5 Although this response rate was much higher than that of patients with T790M-negative tumors (21-29%), acquired resistance to these agents has emerged even in T790M-positive tumors. 4, 5 We previously reported that two EGFR-mutated lung adenocarcinoma cell lines, HCC827 and HCC4006, have subpopulations of cells that display an epithelial-mesenchymal transition (EMT) phenotype and depend on enhanced autophagy, but not on EGFR activity, for survival. 6 We surmise that these EGFR-mutant cells devoid of EGFR dependency lie at the root of TKI resistance.
Protein phosphorylation is a fundamental mode of intracellular signaling in many cellular processes such as proliferation and differentiation. The peptidyl-prolyl isomerase Pin1 has been identified as a regulator that catalyzes cis-trans isomerization of phosphorylated Ser/Thr-Pro motifs in a subset of phosphorylated proteins. [7] [8] [9] [10] Pin1 reportedly activates at least 32 oncogenes and inactivates at least 19 tumor-suppressor genes. 10 Pin1 also seems to have a key role in driving the expansion of breast cancer stem cells and induced pluripotent stem cells. 7, 8 We hypothesized that Pin1 contributes to, at least partly, the acquired resistance of EGFR-mutant lung carcinoma cells to EGFR TKIs because the EGFR TKI-resistant cells derived from HCC827 or HCC4006 cells mentioned above showed much higher expression of the CD44 protein, a cancer stem cell marker, than respective parental cells, 6 which suggests stemness of the TKI-resistant cells.
The objectives of this study were (1) to investigate whether another EGFR-mutant lung adenocarcinoma cell line, H1975 cells harboring the L858R+T790M mutations, contains a subset of cells that can survive in the presence of third-generation EGFR TKIs; moreover, if this is the case, (2) to determine whether and to what extent Pin1 contributes to the increased resistance to EGFR TKI-induced apoptosis.
In the present report, we demonstrate that (1) a subpopulation of H1975 cells that is resistant to WZ4002, a third-generation EGFR TKI, 11 exhibits an EMT phenotype; (2) WZ4002-resistant (WR) cells rely on not only enhanced autophagy but also on Pin1 activity for survival; and (3) Pin1 is clearly expressed in a gefitinib-resistant pleural lesion obtained from an EGFR-mutant lung cancer patient.
MATERIALS AND METHODS
The Institutional Review Board at the Sapporo Medical University approved the following experimental procedures.
Cell Culture and Drugs
The EGFR-mutant lung adenocarcinoma cell line H1975 (L858R+T790M) was purchased from the American Type Culture Collection (Manassas, VA, USA) and maintained in RPMI1640 media containing 10% fetal calf serum and antibiotics at 37°C in a humidified incubator with 5% CO 2 . Two third-generation EGFR TKIs, WZ4002 (Axon Medchem, Groningen, the Netherlands) and CO-1686 (Active Biochem, Wanchai, Hong Kong) were used in this study. 2, 11 Stock solutions of the drugs were prepared at 10 mM in dimethyl sulfoxide.
Generation of WR H1975 Cells H1975 cells (5.0 × 10 5 cells) were seeded in 94-mm tissue culture dishes and received WZ4002 (1 μM) treatment 24 h after seeding. Fresh media containing the drug were replaced every 3 d. Although the drug initially suppressed the growth of the H1975 cells, the cells resumed proliferating in the presence of WZ4002 after 2 weeks of drug selection. The cells that proliferated to subconfluence in a culture dish were trypsinized and then resuspended as single cells in fresh media with the drug. The cells that were seeded again on culture plates were able to thrive in drug-containing media. After the cells survived five passages in the presence of 1 μM WZ4002, single-cell cloning was performed using cloning cylinders. WR subclones were successfully expanded in media containing 1 μM WZ4002 and were termed H1975 WR6-8 cells in this study. We confirmed that each WR subline had the same double mutations (L858R+T790M) in the EGFR gene as its parental cell by loop-hybrid mobility shift assay. 6, 12 Immunofluorescence Staining of Cells Cells grown on ϕ35-mm glass-bottom, collagen-coated dishes (D11134H; Matsunami Glass, Osaka, Japan) were fixed with an ethanol and acetone mixture (1:1) at − 20°C for 10 min for microtubule-associated protein 1 light chain 3 A (LC3A) staining. For staining of Pin1, cells were fixed with 4% paraformaldehyde at room temperature for 15 min, followed by permeabilization with 0.5% Triton X-100 for 5 min. After the cells were rinsed with TBS, they were incubated with anti-LC3A rabbit monoclonal antibody (D50G8; 1:400 dilution; Cell Signaling Technology, Tokyo, Japan) or anti-Pin1 mouse monoclonal antibody (G-8; 1:1000 dilution; Santa Cruz Biotechnology, Santa Cruz, CA, USA) in TBS overnight at 4°C. Alexa Fluor 488-conjugated goat anti-rabbit IgG or Alexia Fluor 488-conjugated donkey anti-mouse IgG (1:200 dilution; Molecular Probes, ThermoFisher Scientific, Yokohama, Japan) was used as a secondary antibody. We also used Alexia Fluor 594-conjugated Phalloidin (1:200 dilution; Molecular Probes) for staining of fibrous actin. After mounting of cells and staining nuclei using SlowFade Diamond Antifade Mountant with DAPI (Molecular Probes), cells were observed via fluorescent microscopy (IX71; Olympus, Tokyo, Japan) and then photographed with DP80, a CCD camera (Olympus).
RNA Interference Assay
Cells (2 × 10 6 ) were plated in 94-mm culture dishes and transfected with negative control siRNA duplexes (1027281; Qiagen, Valencia, CA, USA) or siRNA duplexes targeting ATG5 (SI02655310; Qiagen), ATG7 (SI02655373; Qiagen), or Pin1 using Lipofectamine RNAiMAX Reagent and OPTI-MEM I (ThermoFisher Scientific) according to the manufacturer's recommendations. Two types of siRNA duplexes used for transient Pin1 knockdown were Silencer Select Validated siRNA (Ambion #10546; ThermoFisher Scientific) and siGENOME siRNA Smart pool (GE Healthcare, Buckinghamshire, England). Downregulation of the expression of the targeted genes was verified using western blotting.
Quantitative RT-PCR Total cellular RNA was extracted with the RNeasy Mini Kit (Qiagen), and 1 μg of total RNA was reverse-transcribed into cDNA using the QuantiTect Reverse Transcription Kit (Qiagen) according to the manufacturer's instructions. Real-time PCR was performed using combination with the QuantiTect Primer Assay and QuantiFast SYBR Green PCR Kit (Qiagen) in a LightCycler Nano (Roche Applied Science, Mannheim, Germany). The amount of β-actin mRNA (Hs_ACTB_2_SG) in each sample was used to standardize the quantity of Pin1 mRNA. The relative Pin1 mRNA (Hs_PIN1_1_SG) expression levels between H1975 parental cells and WR7 cells were calculated by the difference of the threshold cycle (comparative ΔΔC T method) and presented as the average of triplicate experiments.
Western Blotting
Western blotting for the expression of E-cadherin, vimentin, CD44, LC3A, MET, ATG5, total EGFR, phosphorylated EGFR, poly(ADP-ribose) polymerase-1 (PARP-1), γH2AX, total AKT, phospho-AKT, total ERK1/2, phospho-ERK1/2, Mcl-1, Bim, and β-actin was performed as described previously. 6, 13 Additional primary antibodies for immunoblotting were anti-ZEB1 (HPA027524; 1:1000 dilution; Atlas Antibodies, Stockholm, Sweden), anti-ATG7 (D12B11; 1:1000 dilution; Cell Signaling), anti-Pin1 (1:1000 dilution; Cell Signaling), anti-Survivin (71G4B7; 1:1000 dilution; Cell Signaling), and anti-Puma (EP512Y; 1:2000 dilution; Abcam Japan, Tokyo, Japan). Band intensity levels on X-ray films were normalized to β-actin using the Image J software (National Institutes of Health, Bethesda, MD, USA).
Assessment of Cell Viability and Apoptosis
The number of viable cells was estimated using a CellTiter Glo 3D Cell Viability Assay (Promega, Madison, WI, USA) according to the manufacturer's instructions. Apoptosis was assessed by western blot analysis of cleaved PARP-1 or Caspase-Glo 3/7 Assay (Promega), as previously described. 6, 13 The luminescence of viable or apoptotic cells was measured with the Infinite 200 microplate reader (Tecan Japan, Kawasaki, Japan). All results are shown as means ± s.d.
EGFR-Mutant Lung Cancer Tissues
We analyzed EGFR-mutant lung cancer tissues obtained from a female Japanese patient treated at the Sapporo Medical University Hospital. The resected primary tumor in the right lower lobe was an adenocarcinoma with a deletion mutation in exon 19. The T790M mutation was not detected in the primary tumor. At 26 months after surgery, the patient developed right carcinomatous pleurisy. The lesions in the right thoracic cavity responded to gefitinib treatment for 10 months, but later progressed even while the patient was receiving gefitinib or erlotinib. The biopsied specimen taken from the right pleura at progression had the secondary T790M mutation, in addition to the original deletion mutation in EGFR. The mutations mentioned above were confirmed by loop-hybrid mobility shift assay. 6, 12 Immunohistochemistry Immunohistochemical staining was carried out on formalin-fixed, paraffin-embedded tissue sections of lung adenocarcinoma specimens for the expression of Pin1, Cytokeratin 7, thyroid transcription factor 1 (TTF-1), and vimentin. Whole-tissue sections were retrieved using Novocastra Epitope Retrieval Solution 1 pH 6.0 for Pin1 expression or pH 9.0 (Leica Biosystems, Nußloch, Germany) for the other antigens' expression at 100°C for 20 min. The types and dilutions of primary antibodies used were anti-Pin1 (G-8; 1:2500; Santa Cruz Biotechnology), anti-Cytokeratin 7 (N1626; 1:4; Dako Japan, Tokyo, Japan), anti-TTF-1 (IR056; 1:3; Dako), and anti-vimentin (N1521; 1:20; Dako). Immunohistochemical staining was conducted using a Leica BOND-MAX (Leica).
Statistical Analysis
Differences in caspase activity or cell viability between untreated and treated cells were evaluated by paired t-tests. Differences in Pin1 mRNA expression levels between parental and WR7 cells were also evaluated by paired t-tests. P-values less than 0.05 were considered significant. All statistical calculations were performed with the JMP software (JMP for Windows version 7; SAS Institute Japan; Tokyo, Japan). (Figure 1a) . Moreover, western blot analysis showed that E-cadherin, an epithelial marker, was markedly reduced, whereas the expression levels of vimentin, a mesenchymal marker, and ZEB1, an EMT-inducing transcription factor, were elevated in WR7 cells compared with the parental cells (Figure 1b) , indicating that WR7 cells exhibit an EMT phenotype. 14, 15 We also observed abundant expression of CD44s in WR7 cells, but not in parental cells (Figure 1b) . The expression levels of LC3A-II, a reliable marker of active autophagy, [16] [17] [18] in WR7 cells were much higher than that in the parental cells (Figure 1b) , and LC3A puncta, which indicate autophagosome formation, [16] [17] [18] were seen in the cytoplasm of WR7 cells (Figure 1c) , showing that WR7 cells had higher levels of basal autophagy than their parental cells. Moreover, inhibition of the autophagic flux through silencing of ATG5 or ATG7, both of which are autophagy-related genes, [16] [17] [18] significantly decreased the proliferation of WR7 cells (Figure 1d ). These findings indicated that H1975 WR7 cells are dependent on active autophagy for survival and/or proliferation. In addition, Figure 1b shows that only H1975 parental cells, but not WR7 cells, expressed the tyrosine kinase MET, which often contributes to EGFR TKI resistance, 1 suggesting that the kinase does not have a critical role in WR7 cell resistance to EGFR inhibition.
RESULTS

H1975 WR7 Cells
Display an EMT Phenotype and Depend on Enhanced Autophagy for Survival H1975 WR7 cells mostly had elongated filopodia-like protrusions, unlike their parental cells
H1975 WR7 Cells can Thrive in the Presence of CO-1686
H1975 parental cells did not proliferate in the presence of 1 μM CO-1686, another third-generation EGFR TKI, 2 and autophosphorylation of EGFR was completely suppressed (Figures 2a and b) . However, H1975 WR7 cells, in which EGFR phosphorylation was not detected even in the absence of CO-1686, were able to propagate in the presence of 1 μM CO-1686 (Figures 2a and b) . CO-1686 treatment significantly elevated caspase 3/7 activity in H1975 parental cells, but not WR7 cells (Figure 2c ). These results collectively suggested that H1975 parental cells substantially rely on EGFR activity, whereas WR7 cells are not dependent on the kinase for survival and proliferation. We also found that the expression level of total EGFR was clearly upregulated in H1975 WR7 cells following treatment with CO-1686, suggesting that enhanced drug efflux was not responsible for WR7 cell resistance to EGFR TKIs. The isomerase Pin1 was expressed slightly higher at the protein and mRNA levels in WR7 cells than in parental cells (Figures 2a and d) . Immunocytochemistry for Pin1 revealed that Pin1 was mainly located in the nuclei of both cells (Figure 2e ).
WR Cells Depend on Pin1 Activity for Survival
H1975 parental cells proliferated steadily, whereas the proliferation of WR7 cells was almost completely inhibited when the expression of Pin was suppressed by siRNA (Figures 3a and b) . We confirmed that H1975 WR7 cells could hardly grow under Pin1-depleted conditions through another siRNA treatment (Supplementary Figure S1a) . The expression of cleaved PARP-1 (an apoptosis marker) and increased expression of γH2AX (a DNA damage marker) were observed only in WR7 cells, but not in their parental cells, when Pin1 was inhibited (Figure 3b) . Further, Pin knockdown elevated caspase 3/7 activity only in WR7 cells (Figure 3c ), indicating that H1975 WR7 cells underwent massive apoptosis, whereas their parental cells evaded cell death in the absence of Pin1. These findings were supported by the fact that Pin1 depletion dephosphorylated AKT only in WR7 cells, but not in their parental cells (Figure 3b ). Decline in cell proliferation was also observed in Pin1-depleted H1975 WR6 and WR8 cells (Supplementary Figure S1b) . Taken together, these findings suggest that Pin1 promotes (Figure 3b ), although both of these molecules are pro-apoptotic Bcl-2 family proteins and have a critical role in apoptosis induction of lung adenocarcinoma cells. 21 
Pin1 is Expressed in Gefitinib-Resistant EGFR-Mutant Lung Adenocarcinoma Tissue
The primary tumor of the patient was papillary predominant lung adenocarcinoma, and the carcinoma cells, excluding stroma, clearly expressed Cytokeratin 7 (an intermediate filament expressed by alveolar epithelial cells) and TTF-1 (a transcription factor essential for the development of the lung), but were negative for vimentin (Figure 4) . The immunohistochemical expression pattern mentioned above was compatible with that of well-differentiated lung adenocarcinomas. 22, 23 The TKI treatment-naive primary cancer tissue was negative for nuclear expression of Pin1. However, the pleural lesion, which acquired resistance to gefitinib or erlotinib therapy, was mostly composed of spindle cells and lacked the morphology that histologically indicates differentiated lung adenocarcinoma, including papillary and acinar structure (Figure 4) . Moreover, carcinoma cells in the pleural lesion obviously expressed vimentin as well as Cytokeratin 7. In addition, positivity for TTF-1 was markedly declined compared with that in the lung primary lesion. These results suggest that the carcinoma cells in pleura acquired a partial EMT phenotype. 15 Immunohistochemistry also revealed nuclear expression of Pin1 in most of the pleural carcinoma cells.
DISCUSSION
We have demonstrated that (1) an EGFR-mutant lung adenocarcinoma cell line, H1975, with double EGFR mutations (L858R+T790M) contains sublines (WR cells) that can survive and proliferate in the presence of third-generation EGFR TKIs; (2) WR7 cells display an EMT phenotype without EGFR autophosphorylation even in the absence of EGFR TKI and are less dependent on EGFR activity for survival; (3) WR7 cells instead rely upon Pin1 activity for survival and proliferation unlike their parental cells; and (4) nuclear expression of Pin1 was observed only in a gefitinib-resistant pleural lesion, but not in its primary lung adenocarcinoma. Because H1975 cells have a subpopulation of cells that is not highly dependent on EGFR signaling for survival, it seems that EGFR inhibition alone (using any EGFR TKI) cannot eradicate these cells. This is consistent with the experimental findings in a seminal article by Walter et al. 2 However, the present study is the first that suggests the contribution of the peptidyl-prolyl isomerase Pin1 to EGFR TKI resistance in lung adenocarcinoma cells. We also examined clinical samples and found that Pin1 was expressed only in the TKI-resistant pleural lesion, but not the primary lung adenocarcinoma. As carcinoma cells in the pleura, in addition to H1975 WR7 cells, also exhibited an EMT phenotype, we surmise that EMT might induce Pin1 dependency, at least in part, in EGFR-mutant lung carcinoma cells. The experimental findings here suggest a contribution of Pin1 to EGFR TKI resistance in EGFR-mutant cells. The pleural lesion analyzed, which expressed Pin1, was resistant to first-generation but not third-generation EGFR TKIs. Therefore, the carcinoma cells in the pleura were not, strictly speaking, a counterpart of H1975 WR7 cells, which resisted third-generation EGFR TKIs. Although Pin1 knockdown obviously induced apoptosis in H1975 WR7 cells, the specific molecule(s) other than AKT downstream of Pin1 that contributes to apoptosis induction remains to be identified. Although Pin1 has been reported to regulate phosphorylation levels of AKT, 24 it remains unclear why Pin1 depletion dephosphorylated AKT in WR7 cells, but not their parental cells. Other mechanisms in addition to EGFR T790M and EMT have a role in acquired resistance to EGFR TKIs, such as amplification of the MET oncogene, transformation to small-cell lung cancer, and EGFR amplification. 1, 25 Multifocal metastatic tumors in an EGFR-mutant lung cancer patient could grow in the presence of EGFR TKIs through different mechanisms owing to intratumoral heterogeneity. 1, 25 Whether and to what extent Pin1 endows EGFR-mutated carcinoma cells with the potential to resist EGFR TKIs, especially when the carcinoma cells have undergone EMT, should be clarified in future studies. Pin1 has also been reported to mediate tamoxifen resistance in estrogen receptor-positive breast cancer cells. 26 This finding and our experimental results raise the possibility that Pin1 promotes the survival of such carcinoma cells with stemness properties as breast cancer cells devoid of hormone receptor dependence and EGFR-independent EGFR-mutated cells. A previous report has shown that all-trans retinoic acid, a drug for acute Pin1 dependence in EGFR-mutant cells Y Sakuma et al promyelocytic leukemia, directly binds to and degrades Pin1; 10 thus, this agent might be effective against Pin1 activity in lung cancer treatment.
We also showed that WR7 cells have a higher degree of basal autophagy than their parental cells and depend highly on continuous autophagic flux for survival. This is in line with previous articles, including ours, that have demonstrated the dependence of EGFR TKI-resistant lung carcinoma cells upon augmented autophagy. 6, 27, 28 It seems that EGFR-mutated carcinoma cells that have lost dependence on kinase activity usually exhibit enhanced autophagic flux as a compensatory mechanism for survival. Therefore, autophagy inhibition might be effective at eradicating TKI-resistant cells.
In conclusion, the H1975 EGFR-mutant lung cancer cell line has a subset of WR cells that has undergone EMT and can thrive in the presence of third-generation EGFR TKIs. H1975 WR7 cells are dependent on Pin1 activity as well as on enhanced autophagy for survival. Furthermore, Pin1 was expressed only in an EGFR-mutant lung adenocarcinoma tissue that has undergone partial EMT and acquired gefitinib resistance. Targeting Pin1 could be a valuable new approach to treat such cancers.
